DeepTek.ai recently unveiled Augmento X-Ray, an innovative Computer-Aided Detection (CADe) Chest X-Ray AI solution, at the Radiology Society of North America’s 109th Annual Meeting. Augmento X-Ray, powered by the US FDA Cleared CXR AI, aims to revolutionize chest X-ray reporting while significantly reducing radiologist workload.
This AI-driven solution addresses a crucial need within medical imaging. With chest radiography being the primary tool for identifying various diseases and approximately 1.5 billion chest examinations performed annually out of 3.5 billion X-rays, the demand for accurate interpretations is vital. However, due to overwhelming workloads and a shortage of experienced radiologists, timely reporting of every image remains a challenge, potentially resulting in missed detections.
Augmento X-Ray steps in to alleviate this strain, boasting an impressive capability to reduce radiologist workload by 30-50%. By effectively distinguishing chest radiographs without suspicions from those warranting further attention, it aids in reducing the backlog of chest X-rays, streamlining radiology workflows, and ultimately enhancing patient care.
Leveraging the US FDA Cleared AI solution CXR Analyzer, Augmento X-Ray offers comprehensive coverage of the entire chest area. It provides in-depth analysis for a wide array of lung, pleura, and cardiac findings, and detects foreign bodies and hardware within the chest.
Ajit Patil, Co-Founder of DeepTek, highlighted the significance of Augmento X-Ray, emphasizing its recent US FDA clearance and the potential it holds in improving healthcare delivery in the US market. Patil envisions the expansion of their reach, facilitating enhanced patient care.
DeepTek’s AI solutions have already made substantial strides in India and the Asia-Pacific region, impacting over a million lives annually across 500 hospitals and imaging centres. Augmento Enterprise, DeepTek’s US FDA-approved platform, has been selected as Singapore’s national radiology AI platform, contributing to productivity and care quality in public hospitals.
Based in Pune, DeepTek.ai comprises around 200 members and collaborates with esteemed partners like TATA Capital, NTT DATA Japan, and Shimadzu Asia Pacific. As the company gears up to venture into the US market, it plans to capitalize on its recent product launch and FDA approvals to make a substantial global impact in the healthcare landscape.
